Skip to main content

Advertisement

Figure 2 | BMC Cancer

Figure 2

From: Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy

Figure 2

Prognostic analysis of NACRT. A: Disease-free survival (DFS) of the patients stratified by the treatment method. The DFS of the patients with NACRT was significantly better than that of the non-NARCT patients (median DFS 12.6 mos for the NACRT group vs. 4.3 mos for the non-NACRT group; P = 0.0056). B: Overall survival (OS) for patients stratified by the treatment method. The OS of the NACRT group was significantly better than that of the non-NACRT group (median OS 26.8 mos for the NACRT group vs. 10.8 mos for the non-NACRT group; P = 0.0158).

Back to article page